Results 321 to 330 of about 580,532 (393)
Dual-morphology Bundle Branch Re-entrant Ventricular Tachycardia in Non-dilated Cardiomyopathy. [PDF]
Alshaghdali I+4 more
europepmc +1 more source
Transcriptomic and cellular analyses of BubR1 hypomorphic hearts reveal disruptions in key pathways and upregulation of markers linked to impaired cardiac structure and function. Comparative transcriptomic analysis shows that BubR1 insufficiency mirrors changes seen in aged and failing hearts. A key finding of this study is that BubR1 levels decline in
Renju Pun+13 more
wiley +1 more source
High‐risk cardiac patients may benefit from timely temporary mechanical circulatory support (tMCS) implantation to provide perioperative hemodynamic stabilization and circulatory support, thus enabling them to undergo life‐saving thoracic surgery. CPB: cardiopulmonary bypass; IABP: intra‐aortic balloon pump; tMCS: temporary mechanical circulatory ...
Viviana Teresa Agosta+4 more
wiley +1 more source
Radiomic Cardiac MRI Signatures for Predicting Ventricular Arrhythmias in Patients With Nonischemic Dilated Cardiomyopathy. [PDF]
Amyar A+10 more
europepmc +1 more source
The IC direction in HM3 was influenced by the mitral valve height from the LV apex, distance between the LV apex and chest wall, and thoracic depth from the LV apex. Moreover, the IC direction in HM3 had little influence on the flow, PAWP and the survival rate of patients.
Shusuke Imaoka+8 more
wiley +1 more source
Left Ventricular Unloading in Nonischemic Dilated Cardiomyopathy Improves Coronary Haemodynamic Reserve. [PDF]
Fawaz S+9 more
europepmc +1 more source
Mitochondria associated membranes in dilated cardiomyopathy: connecting pathogenesis and cellular dysfunction. [PDF]
He P, Chang H, Qiu Y, Wang Z.
europepmc +1 more source
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen+3 more
wiley +1 more source